APO Research
Talk to an analyst

APO RESEARCH · REPORT

Venous Thromboembolism Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Venous Thromboembolism Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026193 pages

Choose your research edition.

Industry ResearchVenous Thromboembolism Drug Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Venous Thromboembolism Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Venous Thromboembolism Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Venous Thromboembolism Drug Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Venous Thromboembolism Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Venous Thromboembolism Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Venous Thromboembolism Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Venous Thromboembolism Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Venous Thromboembolism Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Venous Thromboembolism Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Venous Thromboembolism Drug include Sanofi, J&J, Bayer, Gamma Therapeutics, eXIthera Pharmaceuticals, Daiichi Sankyo, Boehringer Ingelheim, BMS and BioInvent, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Venous Thromboembolism Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Venous Thromboembolism Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Venous Thromboembolism Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Venous Thromboembolism Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Venous Thromboembolism Drug Segment by Company

Sanofi

J&J

Bayer

Gamma Therapeutics

eXIthera Pharmaceuticals

Daiichi Sankyo

Boehringer Ingelheim

BMS

BioInvent

Aspen Pharma

Armetheon

Altor Bioscience

Venous Thromboembolism Drug Segment by Type

Rivaroxaban

Warfarin

Heparin

Dabigatran

Edaxaban

Apixaban

Venous Thromboembolism Drug Segment by Application

Hospital

Clinic

Venous Thromboembolism Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Venous Thromboembolism Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Venous Thromboembolism Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Venous Thromboembolism Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Venous Thromboembolism Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Venous Thromboembolism Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Venous Thromboembolism Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Venous Thromboembolism Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Venous Thromboembolism Drug Industry Trends Table 2. Venous Thromboembolism Drug Industry Drivers Table 3. Venous Thromboembolism Drug Industry Opportunities and Challenges Table 4. Venous Thromboembolism Drug Industry Restraints Table 5. Global Venous Thromboembolism Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Venous Thromboembolism Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Venous Thromboembolism Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Venous Thromboembolism Drug Sales Market Share by Manufacturers Table 9. Global Venous Thromboembolism Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Venous Thromboembolism Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Venous Thromboembolism Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Venous Thromboembolism Drug Manufacturers, Product Type & Application Table 13. Global Venous Thromboembolism Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Venous Thromboembolism Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Rivaroxaban Table 17. Major Manufacturers of Warfarin Table 18. Major Manufacturers of Heparin Table 19. Major Manufacturers of Dabigatran Table 20. Major Manufacturers of Edaxaban Table 21. Major Manufacturers of Apixaban Table 22. Global Venous Thromboembolism Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Venous Thromboembolism Drug Sales by Type (2021-2026) & (K Units) Table 24. Global Venous Thromboembolism Drug Sales by Type (2027-2032) & (K Units) Table 25. Global Venous Thromboembolism Drug Sales Market Share by Type (2021-2026) Table 26. Global Venous Thromboembolism Drug Sales Market Share by Type (2027-2032) Table 27. Global Venous Thromboembolism Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global Venous Thromboembolism Drug Revenue by Type (2021-2026) & (K Units) Table 29. Global Venous Thromboembolism Drug Revenue by Type (2027-2032) & (K Units) Table 30. Global Venous Thromboembolism Drug Revenue Market Share by Type (2021-2026) Table 31. Global Venous Thromboembolism Drug Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Hospital Table 33. Major Manufacturers of Clinic Table 34. Global Venous Thromboembolism Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Venous Thromboembolism Drug Sales by Application (2021-2026) & (K Units) Table 36. Global Venous Thromboembolism Drug Sales by Application (2027-2032) & (K Units) Table 37. Global Venous Thromboembolism Drug Sales Market Share by Application (2021-2026) Table 38. Global Venous Thromboembolism Drug Sales Market Share by Application (2027-2032) Table 39. Global Venous Thromboembolism Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Venous Thromboembolism Drug Revenue by Application (2021-2026) & (K Units) Table 41. Global Venous Thromboembolism Drug Revenue by Application (2027-2032) & (K Units) Table 42. Global Venous Thromboembolism Drug Revenue Market Share by Application (2021-2026) Table 43. Global Venous Thromboembolism Drug Revenue Market Share by Application (2027-2032) Table 44. Global Venous Thromboembolism Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Venous Thromboembolism Drug Sales by Region (2021-2026) & (K Units) Table 46. Global Venous Thromboembolism Drug Sales Market Share by Region (2021-2026) Table 47. Global Venous Thromboembolism Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Venous Thromboembolism Drug Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Venous Thromboembolism Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Venous Thromboembolism Drug Sales by Country (2021-2026) & (K Units) Table 51. North America Venous Thromboembolism Drug Sales by Country (2027-2032) & (K Units) Table 52. Europe Venous Thromboembolism Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Venous Thromboembolism Drug Sales by Country (2021-2026) & (K Units) Table 54. Europe Venous Thromboembolism Drug Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Venous Thromboembolism Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Venous Thromboembolism Drug Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Venous Thromboembolism Drug Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Venous Thromboembolism Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Venous Thromboembolism Drug Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Venous Thromboembolism Drug Sales by Country (2027-2032) & (K Units) Table 61. Global Venous Thromboembolism Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Venous Thromboembolism Drug Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Venous Thromboembolism Drug Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Venous Thromboembolism Drug Revenue Market Share by Region (2021-2026) Table 65. Global Venous Thromboembolism Drug Revenue Market Share by Region (2027-2032) Table 66. Sanofi Company Information Table 67. Sanofi Business Overview Table 68. Sanofi Venous Thromboembolism Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Sanofi Venous Thromboembolism Drug Product Portfolio Table 70. Sanofi Recent Development Table 71. J&J Company Information Table 72. J&J Business Overview Table 73. J&J Venous Thromboembolism Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. J&J Venous Thromboembolism Drug Product Portfolio Table 75. J&J Recent Development Table 76. Bayer Company Information Table 77. Bayer Business Overview Table 78. Bayer Venous Thromboembolism Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Bayer Venous Thromboembolism Drug Product Portfolio Table 80. Bayer Recent Development Table 81. Gamma Therapeutics Company Information Table 82. Gamma Therapeutics Business Overview Table 83. Gamma Therapeutics Venous Thromboembolism Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Gamma Therapeutics Venous Thromboembolism Drug Product Portfolio Table 85. Gamma Therapeutics Recent Development Table 86. eXIthera Pharmaceuticals Company Information Table 87. eXIthera Pharmaceuticals Business Overview Table 88. eXIthera Pharmaceuticals Venous Thromboembolism Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. eXIthera Pharmaceuticals Venous Thromboembolism Drug Product Portfolio Table 90. eXIthera Pharmaceuticals Recent Development Table 91. Daiichi Sankyo Company Information Table 92. Daiichi Sankyo Business Overview Table 93. Daiichi Sankyo Venous Thromboembolism Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Daiichi Sankyo Venous Thromboembolism Drug Product Portfolio Table 95. Daiichi Sankyo Recent Development Table 96. Boehringer Ingelheim Company Information Table 97. Boehringer Ingelheim Business Overview Table 98. Boehringer Ingelheim Venous Thromboembolism Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Boehringer Ingelheim Venous Thromboembolism Drug Product Portfolio Table 100. Boehringer Ingelheim Recent Development Table 101. BMS Company Information Table 102. BMS Business Overview Table 103. BMS Venous Thromboembolism Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. BMS Venous Thromboembolism Drug Product Portfolio Table 105. BMS Recent Development Table 106. BioInvent Company Information Table 107. BioInvent Business Overview Table 108. BioInvent Venous Thromboembolism Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. BioInvent Venous Thromboembolism Drug Product Portfolio Table 110. BioInvent Recent Development Table 111. Aspen Pharma Company Information Table 112. Aspen Pharma Business Overview Table 113. Aspen Pharma Venous Thromboembolism Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Aspen Pharma Venous Thromboembolism Drug Product Portfolio Table 115. Aspen Pharma Recent Development Table 116. Armetheon Company Information Table 117. Armetheon Business Overview Table 118. Armetheon Venous Thromboembolism Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Armetheon Venous Thromboembolism Drug Product Portfolio Table 120. Armetheon Recent Development Table 121. Altor Bioscience Company Information Table 122. Altor Bioscience Business Overview Table 123. Altor Bioscience Venous Thromboembolism Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Altor Bioscience Venous Thromboembolism Drug Product Portfolio Table 125. Altor Bioscience Recent Development Table 126. Key Raw Materials Table 127. Raw Materials Key Suppliers Table 128. Venous Thromboembolism Drug Distributors List Table 129. Venous Thromboembolism Drug Customers List Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Venous Thromboembolism Drug Product Image Figure 2. Global Venous Thromboembolism Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Venous Thromboembolism Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Venous Thromboembolism Drug Sales (2021-2032) & (K Units) Figure 5. Global Venous Thromboembolism Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Venous Thromboembolism Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Rivaroxaban Image Figure 9. Warfarin Image Figure 10. Heparin Image Figure 11. Dabigatran Image Figure 12. Edaxaban Image Figure 13. Apixaban Image Figure 14. Global Venous Thromboembolism Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Venous Thromboembolism Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Venous Thromboembolism Drug Sales Market Share by Type (2021-2032) Figure 17. Global Venous Thromboembolism Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Venous Thromboembolism Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Venous Thromboembolism Drug Revenue Market Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Global Venous Thromboembolism Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Venous Thromboembolism Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Venous Thromboembolism Drug Sales Market Share by Application (2021-2032) Figure 25. Global Venous Thromboembolism Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Venous Thromboembolism Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Venous Thromboembolism Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Venous Thromboembolism Drug Sales Market Share by Country (2021-2032) Figure 30. U.S. Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Venous Thromboembolism Drug Sales Market Share by Country (2021-2032) Figure 35. Germany Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Venous Thromboembolism Drug Sales Market Share by Country (2021-2032) Figure 42. China Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Venous Thromboembolism Drug Sales Market Share by Country (2021-2032) Figure 50. Brazil Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Venous Thromboembolism Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Venous Thromboembolism Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Venous Thromboembolism Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Venous Thromboembolism Drug Revenue (2021-2032) & (US$ Million) Figure 61. North America Venous Thromboembolism Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Venous Thromboembolism Drug Revenue (2021-2032) & (US$ Million) Figure 63. Europe Venous Thromboembolism Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Venous Thromboembolism Drug Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Venous Thromboembolism Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Venous Thromboembolism Drug Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Venous Thromboembolism Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Venous Thromboembolism Drug Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Venous Thromboembolism Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Rivaroxaban
  • Warfarin
  • Heparin
  • Dabigatran
  • Edaxaban
  • Apixaban
Applications
  • Hospital
  • Clinic
Companies covered
  • Sanofi
  • J&J
  • Bayer
  • Gamma Therapeutics
  • eXIthera Pharmaceuticals
  • Daiichi Sankyo
  • Boehringer Ingelheim
  • BMS
  • BioInvent
  • Aspen Pharma
  • Armetheon
  • Altor Bioscience

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Venous Thromboembolism Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Venous Thromboembolism Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Venous Thromboembolism Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Venous Thromboembolism Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Venous Thromboembolism Drug Market Dynamics
  1. 2.1 Venous Thromboembolism Drug Industry Trends
  2. 2.2 Venous Thromboembolism Drug Industry Drivers
  3. 2.3 Venous Thromboembolism Drug Industry Opportunities and Challenges
  4. 2.4 Venous Thromboembolism Drug Industry Restraints
3 Venous Thromboembolism Drug Market by Manufacturers
  1. 3.1 Global Venous Thromboembolism Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Venous Thromboembolism Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Venous Thromboembolism Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Venous Thromboembolism Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Venous Thromboembolism Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Venous Thromboembolism Drug Manufacturers, Product Type & Application
  7. 3.7 Global Venous Thromboembolism Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Venous Thromboembolism Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Venous Thromboembolism Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Venous Thromboembolism Drug Tier 1, Tier 2, and Tier 3
4 Venous Thromboembolism Drug Market by Type
  1. 4.1 Venous Thromboembolism Drug Type Introduction
  2. 4.1.1 Rivaroxaban
  3. 4.1.2 Warfarin
  4. 4.1.3 Heparin
  5. 4.1.4 Dabigatran
  6. 4.1.5 Edaxaban
  7. 4.1.6 Apixaban
  8. 4.2 Global Venous Thromboembolism Drug Sales by Type
  9. 4.2.1 Global Venous Thromboembolism Drug Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Venous Thromboembolism Drug Sales by Type (2021-2032)
  11. 4.2.3 Global Venous Thromboembolism Drug Sales Market Share by Type (2021-2032)
  12. 4.3 Global Venous Thromboembolism Drug Revenue by Type
  13. 4.3.1 Global Venous Thromboembolism Drug Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Venous Thromboembolism Drug Revenue by Type (2021-2032)
  15. 4.3.3 Global Venous Thromboembolism Drug Revenue Market Share by Type (2021-2032)
5 Venous Thromboembolism Drug Market by Application
  1. 5.1 Venous Thromboembolism Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Venous Thromboembolism Drug Sales by Application
  5. 5.2.1 Global Venous Thromboembolism Drug Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Venous Thromboembolism Drug Sales by Application (2021-2032)
  7. 5.2.3 Global Venous Thromboembolism Drug Sales Market Share by Application (2021-2032)
  8. 5.3 Global Venous Thromboembolism Drug Revenue by Application
  9. 5.3.1 Global Venous Thromboembolism Drug Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Venous Thromboembolism Drug Revenue by Application (2021-2032)
  11. 5.3.3 Global Venous Thromboembolism Drug Revenue Market Share by Application (2021-2032)
6 Global Venous Thromboembolism Drug Sales by Region
  1. 6.1 Global Venous Thromboembolism Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Venous Thromboembolism Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Venous Thromboembolism Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Venous Thromboembolism Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Venous Thromboembolism Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Venous Thromboembolism Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Venous Thromboembolism Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Venous Thromboembolism Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Venous Thromboembolism Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Venous Thromboembolism Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Venous Thromboembolism Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Venous Thromboembolism Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Venous Thromboembolism Drug Revenue by Region
  1. 7.1 Global Venous Thromboembolism Drug Revenue by Region
  2. 7.1.1 Global Venous Thromboembolism Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Venous Thromboembolism Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Venous Thromboembolism Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Venous Thromboembolism Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Venous Thromboembolism Drug Revenue (2021-2032)
  8. 7.2.2 North America Venous Thromboembolism Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Venous Thromboembolism Drug Revenue (2021-2032)
  11. 7.3.2 Europe Venous Thromboembolism Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Venous Thromboembolism Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Venous Thromboembolism Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Venous Thromboembolism Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Venous Thromboembolism Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Venous Thromboembolism Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Venous Thromboembolism Drug Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 J&J
  8. 8.2.1 J&J Company Information
  9. 8.2.2 J&J Business Overview
  10. 8.2.3 J&J Venous Thromboembolism Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 J&J Venous Thromboembolism Drug Product Portfolio
  12. 8.2.5 J&J Recent Developments
  13. 8.3 Bayer
  14. 8.3.1 Bayer Company Information
  15. 8.3.2 Bayer Business Overview
  16. 8.3.3 Bayer Venous Thromboembolism Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bayer Venous Thromboembolism Drug Product Portfolio
  18. 8.3.5 Bayer Recent Developments
  19. 8.4 Gamma Therapeutics
  20. 8.4.1 Gamma Therapeutics Company Information
  21. 8.4.2 Gamma Therapeutics Business Overview
  22. 8.4.3 Gamma Therapeutics Venous Thromboembolism Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Gamma Therapeutics Venous Thromboembolism Drug Product Portfolio
  24. 8.4.5 Gamma Therapeutics Recent Developments
  25. 8.5 eXIthera Pharmaceuticals
  26. 8.5.1 eXIthera Pharmaceuticals Company Information
  27. 8.5.2 eXIthera Pharmaceuticals Business Overview
  28. 8.5.3 eXIthera Pharmaceuticals Venous Thromboembolism Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 eXIthera Pharmaceuticals Venous Thromboembolism Drug Product Portfolio
  30. 8.5.5 eXIthera Pharmaceuticals Recent Developments
  31. 8.6 Daiichi Sankyo
  32. 8.6.1 Daiichi Sankyo Company Information
  33. 8.6.2 Daiichi Sankyo Business Overview
  34. 8.6.3 Daiichi Sankyo Venous Thromboembolism Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Daiichi Sankyo Venous Thromboembolism Drug Product Portfolio
  36. 8.6.5 Daiichi Sankyo Recent Developments
  37. 8.7 Boehringer Ingelheim
  38. 8.7.1 Boehringer Ingelheim Company Information
  39. 8.7.2 Boehringer Ingelheim Business Overview
  40. 8.7.3 Boehringer Ingelheim Venous Thromboembolism Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Boehringer Ingelheim Venous Thromboembolism Drug Product Portfolio
  42. 8.7.5 Boehringer Ingelheim Recent Developments
  43. 8.8 BMS
  44. 8.8.1 BMS Company Information
  45. 8.8.2 BMS Business Overview
  46. 8.8.3 BMS Venous Thromboembolism Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 BMS Venous Thromboembolism Drug Product Portfolio
  48. 8.8.5 BMS Recent Developments
  49. 8.9 BioInvent
  50. 8.9.1 BioInvent Company Information
  51. 8.9.2 BioInvent Business Overview
  52. 8.9.3 BioInvent Venous Thromboembolism Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 BioInvent Venous Thromboembolism Drug Product Portfolio
  54. 8.9.5 BioInvent Recent Developments
  55. 8.10 Aspen Pharma
  56. 8.10.1 Aspen Pharma Company Information
  57. 8.10.2 Aspen Pharma Business Overview
  58. 8.10.3 Aspen Pharma Venous Thromboembolism Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Aspen Pharma Venous Thromboembolism Drug Product Portfolio
  60. 8.10.5 Aspen Pharma Recent Developments
  61. 8.11 Armetheon
  62. 8.11.1 Armetheon Company Information
  63. 8.11.2 Armetheon Business Overview
  64. 8.11.3 Armetheon Venous Thromboembolism Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Armetheon Venous Thromboembolism Drug Product Portfolio
  66. 8.11.5 Armetheon Recent Developments
  67. 8.12 Altor Bioscience
  68. 8.12.1 Altor Bioscience Company Information
  69. 8.12.2 Altor Bioscience Business Overview
  70. 8.12.3 Altor Bioscience Venous Thromboembolism Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Altor Bioscience Venous Thromboembolism Drug Product Portfolio
  72. 8.12.5 Altor Bioscience Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Venous Thromboembolism Drug Value Chain Analysis
  2. 9.1.1 Venous Thromboembolism Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Venous Thromboembolism Drug Production Mode & Process
  6. 9.2 Venous Thromboembolism Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Venous Thromboembolism Drug Distributors
  9. 9.2.3 Venous Thromboembolism Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst